Get 30% off on our Global Market Reports with code ONLINE30 – Hurry, limited time offer!
How Has The Genomic Urine Testing Market Growth Evolved From 2024 To 2025, And What’s Ahead?
In recent times, there has been a swift expansion in the market size of genomic urine testing. The market is predicted to escalate from $0.90 billion in 2024 to $1.01 billion in 2025, exhibiting a compound annual growth rate of 12.9%. The surge in growth during the historic period is associated with factors such as a rise in the occurrence of urologic cancers, a growing urge for early recognition of cancer, increasing awareness about precision medicine, a rise in the frequency of genetic disorders, and augmented investments in biomarker discovery.
In the coming years, the genomic urine testing market is projected to experience significant expansion. The market value is anticipated to reach $1.62 billion by 2029, with a compound annual growth rate (CAGR) of 12.5%. This projected growth during the forecast period is due to several factors including the rise in liquid biopsy techniques, an increasing focus on individualized medicine, escalating prevalence of chronic kidney diseases, a surge in demand for home-based diagnostic testing options and a growing application of multi-omics approaches in urine testing. Key trends for the forecast period include advancement of non-invasive diagnostic pathways, the creation of highly sensitive test panels, the integration of machine learning workflows, development in urine exosome isolation and innovation in single-cell urine sequencing.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23408&type=smp
What Are the Primary Drivers Supporting the Market Growth of the Genomic Urine Testing Market?
The escalating issue of chronic kidney disease is projected to fuel the expansion of the genomic urine testing market in the future. Chronic kidney disease denotes a state wherein the kidneys are impaired and lose their ability to effectively filter blood, leading to an accumulation of waste and fluids in one’s body. The growing incidence of diabetes, due to high sugar levels damaging kidney blood vessels and affecting their waste-filtering capabilities, is leading to a rise in chronic kidney disease cases. Genomic urine testing plays a crucial role in managing chronic kidney disease, by facilitating the early identification of genetic markers, providing ample time for interventions, and designing personalized treatment strategies. It tremendously improves patient outcomes by permitting more precise monitoring and slowing down the disease’s progression. For instance, the chronic kidney disease mortality rates, according to Australian Institute of Health and Welfare, a government agency based in Australia, witnessed an increase from 4.2% in 2021 to 6.2% in 2022, in June 2024. Thus, the escalating issue of chronic kidney disease is accelerating the expansion of the genomic urine testing market.
Which Primary Segments of the Genomic Urine Testing Market Are Driving Growth and Industry Transformations?
The genomic urine testing market covered in this report is segmented –
1) By Testing Type: Deoxyribonucleic Acid (DNA) Testing, Ribonucleic Acid (RNA) Testing, Microbial Testing, Epigenetic Testing
2) By Distribution Channel: Hospital Pharmacies, Mail Order Pharmacies, Speciality Pharmacies
3) By Application: Cancer Diagnosis, Infectious Diseases, Genetic Disorder Screening, Health Monitoring
4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutions, Other End Users
Subsegments
1) By Deoxyribonucleic Acid Testing: Germline Mutation Analysis, Somatic Mutation Detection, Copy Number Variation (CNV) Testing, Single Nucleotide Polymorphism Analysis
2) By Ribonucleic Acid Testing: Gene Expression Profiling, Messenger Ribonucleic Acid Analysis, Non-coding Ribonucleic Acid Detection, Fusion Transcript Detection
3) By Microbial Testing: Urinary Microbiome Profiling, Pathogen Identification, Antimicrobial Resistance Gene Detection, Quantitative Microbial Load Analysis
4) By Epigenetic Testing: Deoxyribonucleic Acid Methylation Analysis, Histone Modification Profiling, Chromatin Accessibility Testing
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=23408&type=smp
Which Regions Are Key Players in the Growth of the Genomic Urine Testing Market?
North America was the largest region in the genomic urine testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic urine testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Current Market Growth and Trends in the Genomic Urine Testing Industry?
Leading entities in the genomic urine testing market are channeling their focus into innovating solutions such as next-generation sequencing in order to boost the precision, sensitivity, and early detection aspects of non-invasive diagnostic exams for a variety of conditions. Next-gen sequencing, or NGS, is a sophisticated DNA sequencing process that facilitates quick, exact, and large-scale scrutiny of genetic material by sequencing millions of DNA fragments all at once. For example, in May 2023, the American biotech firm Convergent Genomics Inc. introduced the genomic urine test called UroAmp. Utilizing next-gen DNA sequencing, this test observes mutations in 60 genes linked to bladder cancer, facilitating early detection up to 12 years prior to the onset of clinical symptoms. It aids in providing comprehensive genetic insights essential for diagnosis, making treatment decisions, and recurrence monitoring, possessing greater precision than conventional methods, including cytology and cystoscopy.
View the full report here:
https://www.thebusinessresearchcompany.com/report/genomic-urine-testing-global-market-report
What Parameters Are Used to Define the Genomic Urine Testing Market?
Genomic urine testing is a non-invasive diagnostic method that analyzes genetic material present in urine to detect specific biomarkers related to diseases, such as cancer, infections, or genetic disorders. It combines genomics with advanced molecular techniques to identify mutations, gene expression patterns, or microbial deoxyribonucleic acid (DNA). The primary purpose is early detection, monitoring, and personalized treatment planning for various health conditions.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23408
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model